Physician profile
Daniel Hwang
NPI 1184678856
$3,693.16
in general payments reported to CMS, 2019-2025
14 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $1,234 · 2021: $228 · 2022: $288 · 2023: $301 · 2024: $521 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,233.68 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $561.99 | 2019-2024 | Dupixent |
| Integra Lifesciences Corporation | $362.86 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aerin Medical INC. | $304.28 | 2024-2025 | |
| Gilead Sciences, INC. | $189.48 | 2019-2021 | |
| Stryker Corporation | $183.29 | 2019-2022 | |
| Inspire Medical Systems, INC. | $181.58 | 2024-2025 | Inspire |
| Genzyme Corporation | $176.35 | 2019-2023 | |
| Glaxosmithkline, LLC. | $146.41 | 2021-2025 | Nucala |
| Allergan, INC. | $124.82 | 2019 | |
| Cochlear Americas | $106.37 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Medtronic, INC. | $78.28 | 2024 | Propel |
| Optinose US, INC. | $25.22 | 2019 | |
| Intersect Ent, INC. | $18.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.